CA-HILLSTONE-NETWORKS
11.5.2022 08:02:09 CEST | Business Wire | Press release
Hillstone Networks , a leading provider of infrastructure protection solutions, today announced it has received “Customers’ Choice” distinction in the 2022 Gartner Peer Insights ‘Voice of the Customer’: Network Firewalls . “Gartner Peer Insights is a free peer review and rating platform designed for enterprise software and services decision makers.”
In the report, vendors, including Hillstone Networks, “placed in the upper-right quadrant of the 'Voice of the Customer' quadrants are recognized with the Gartner Peer Insights Customers’ Choice distinction, denoted with a Customers’ Choice badge. The recognized vendors meet or exceed both the market average Overall Rating and the market average User Interest and Adoption.”
“In addition to delivering innovative, proven, and effective network security solutions, Hillstone Networks is committed to providing a superior customer experience,” said Tim Liu, co-founder & CTO, of Hillstone Networks. “To be recognized with a ‘Customers’ Choice’ distinction, we believe, is a testament to our commitment to provide the exceptional service and support our customers need to keep their companies safe.”
Key findings for Hillstone Networks in the Gartner Peer Insights “Voice of the Customer” Network Firewalls report as of 28th Feb 2022 include:
- Hillstone Networks received a 100 percent “willingness to recommend” rating from its users.
- 85 percent of surveyed Hillstone users gave the company a 5 out of 5 stars rating.
- Hillstone Networks’ Support Experience received a 4.9 out of 5 rating based on 94 reviews.
- Hillstone Networks’ Sales Experience received a 4.9 out of 5 rating based on 93 reviews.
To read the 2022 Gartner Peer Insights “Voice of the Customer” Network Firewalls report, click here.
With over 23,000 global customers, Hillstone Networks has established a reputation of “security that works.” Its intuitive solutions span SD-WAN , ZTNA , Microsegmentation , CWPP , NDR , as well as XDR . Hillstone Networks has been named a Visionary in the Gartner Magic Quadrant™ for Network Firewalls and has also been recognized for eight consecutive years.
Gartner, Gartner Peer Insights ‘Voice of the Customer’: Network Firewalls, Peer Contributors, 29th April 2022. *
Gartner, Magic Quadrant for Network Firewalls, By Rajpreet Kaur, Jeremy D'Hoinne, Nat Smith, Adam Hils, 1 November 2021
Gartner and Magic Quadrant are registered trademarks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved
About Gartner Peer Insight
Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.
Peer Insights is a trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.
Gartner Peer Insights Customers’ Choice constitute the subjective opinions of individual end-user reviews, ratings, and data applied against a documented methodology; they neither represent the views of, nor constitute an endorsement by, Gartner or its affiliates.
About Hillstone Networks
Hillstone Networks’ proven Infrastructure Protection solutions provide enterprises and service providers with the visibility and intelligence to comprehensively see, thoroughly understand, and rapidly act against multilayer, multistage cyberthreats. Favorably rated by leading analysts and trusted by global companies, Hillstone protects from the edge to cloud with improved total-cost-of-ownership. To learn more visit www.hillstonenet.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005419/en/
Link:
Social Media:
https://www.facebook.com/Hillstone-Networks-230976560386832/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
